103 related articles for article (PubMed ID: 24501865)
1. [Evaluation of the expression of S100A1 protein in serous, mucinous and endometroid ovarian carcinoma].
Yordanov A; Ivanov I; Popovska S; Dineva T; Dimitrov T; Ivanova Z
Akush Ginekol (Sofiia); 2013; 52(5):22-6. PubMed ID: 24501865
[TBL] [Abstract][Full Text] [Related]
2. [Investigation of S100A1 expression in normal ovarian tissues].
Ivanov I; Jordanov A; Popovska S; Dineva T; Dimitrov T
Akush Ginekol (Sofiia); 2013; 52(7):13-9. PubMed ID: 24505634
[TBL] [Abstract][Full Text] [Related]
3. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
4. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
5. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
6. [Expression of the cdx2 gene in benign intestinal-type mucinous ovarian tumors].
Gaggero G; Sola S; Mora M; Fulcheri E
Pathologica; 2003 Aug; 95(4):185-91. PubMed ID: 14577202
[TBL] [Abstract][Full Text] [Related]
7. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
8. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
[TBL] [Abstract][Full Text] [Related]
10. Expression of extracellular matrix proteins in ovarian serous tumors.
Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
[TBL] [Abstract][Full Text] [Related]
12. Hypoxic status in ovarian serous and mucinous tumors: relationship between histological characteristics and HIF-1alpha/GLUT-1 expression.
Iida T; Yasuda M; Miyazawa M; Fujita M; Osamura RY; Hirasawa T; Muramatsu T; Murakami M; Saito K; Mikami M
Arch Gynecol Obstet; 2008 Jun; 277(6):539-46. PubMed ID: 18026974
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemical demonstration of CA 125, CA 19-9 and CEA in normal and pathologically changed adnexa].
Neunteufel W; Breitenecker G
Geburtshilfe Frauenheilkd; 1988 May; 48(5):334-7. PubMed ID: 3165079
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
18. The potential prognostic value of cathepsin D protein in serous ovarian cancer.
Chai Y; Wu W; Zhou C; Zhou J
Arch Gynecol Obstet; 2012 Aug; 286(2):465-71. PubMed ID: 22476353
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 expression in borderline ovarian tumors.
Ferrandina G; Zannoni GF; Ranelletti FO; Legge F; Gessi M; Salutari V; Gallotta V; Lauriola L; Scambia G
Gynecol Oncol; 2004 Oct; 95(1):46-51. PubMed ID: 15385109
[TBL] [Abstract][Full Text] [Related]
20. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas.
Dong Y; Kaushal A; Bui L; Chu S; Fuller PJ; Nicklin J; Samaratunga H; Clements JA
Clin Cancer Res; 2001 Aug; 7(8):2363-71. PubMed ID: 11489814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]